BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR448501 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR448501\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06392477-5413@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20280121
DTEND;VALUE=DATE:20280122
SUMMARY:SAR448501: Phase 1 readout est. (NCT06392477)
DESCRIPTION:SAR448501\, phase 1.\nStudy: A Study to Evaluate the Safety and
  Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cel
 l Non-Hodgkin Lymphoma\nEstimated primary completion: 21 January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sar448501#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06392477
URL:https://assetmemo.bio/drug/sar448501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647069-5413@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20290625
DTEND;VALUE=DATE:20290626
SUMMARY:SAR448501: Phase 1 readout est. (NCT06647069)
DESCRIPTION:SAR448501\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients 
 With Autoimmune Rheumatic Diseases\nEstimated primary completion: 25 June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sar448501#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06647069
URL:https://assetmemo.bio/drug/sar448501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
